Department of Surgery and Cancer, Anaesthetics, Pain Medicine and Intensive Care Section, Blackett Laboratory, Imperial College London. London SW7 2AZ, United Kingdom.
Anesthesiology. 2010 Mar;112(3):623-30. doi: 10.1097/ALN.0b013e3181cf894a.
Adenosine triphosphate-sensitive potassium (KATP) channels in brain are involved in neuroprotective mechanisms. Pharmacologic activation of these channels is seen as beneficial, but clinical exploitation by using classic K channel openers is hampered by their inability to cross the blood-brain barrier. This is different with the inhalational anesthetic xenon, which recently has been suggested to activate KATP channels; it partitions freely into the brain.
To evaluate the type and mechanism of interaction of xenon with neuronal-type KATP channels, these channels, consisting of Kir6.2 pore-forming subunits and sulfonylurea receptor-1 regulatory subunits, were expressed in HEK293 cells and whole cell, and excised patch-clamp recordings were performed.
Xenon, in contrast to classic KATP channel openers, acted directly on the Kir6.2 subunit of the channel. It had no effect on the closely related, adenosine triphosphate (ATP)-regulated Kir1.1 channel and failed to activate an ATP-insensitive mutant version of Kir6.2. Furthermore, concentration-inhibition curves for ATP obtained from inside-out patches in the absence or presence of 80% xenon revealed that xenon reduced the sensitivity of the KATP channel to ATP. This was reflected in an approximately fourfold shift of the concentration causing half-maximal inhibition (IC50) from 26 +/- 4 to 96 +/- 6 microm.
Xenon represents a novel KATP channel opener that increases KATP currents independently of the sulfonylurea receptor-1 subunit by reducing ATP inhibition of the channel. Through this action and by its ability to readily partition across the blood-brain barrier, xenon has considerable potential in clinical settings of neuronal injury, including stroke.
脑内三磷酸腺苷敏感性钾 (KATP) 通道参与神经保护机制。这些通道的药理学激活被认为是有益的,但使用经典的 K 通道开放剂进行临床开发受到其无法穿过血脑屏障的限制。这与吸入麻醉剂氙气不同,氙气最近被认为可以激活 KATP 通道;它可以自由分配到大脑中。
为了评估氙气与神经元型 KATP 通道相互作用的类型和机制,在 HEK293 细胞中表达了由 Kir6.2 孔形成亚基和磺酰脲受体-1 调节亚基组成的这些通道,并进行了全细胞和膜片钳记录。
与经典的 KATP 通道开放剂相比,氙气直接作用于通道的 Kir6.2 亚基。它对密切相关的、三磷酸腺苷 (ATP) 调节的 Kir1.1 通道没有影响,也不能激活 Kir6.2 的非 ATP 敏感突变体版本。此外,在不存在或存在 80%氙气的情况下,从膜内向外片获得的 ATP 浓度-抑制曲线表明,氙气降低了 KATP 通道对 ATP 的敏感性。这反映在导致半最大抑制的浓度(IC50)从 26 ± 4 到 96 ± 6 µm 的约四倍变化。
氙气代表一种新型的 KATP 通道开放剂,通过降低通道对 ATP 的抑制作用,独立于磺酰脲受体-1 亚基增加 KATP 电流。通过这种作用以及其易于穿过血脑屏障的能力,氙气在包括中风在内的神经元损伤的临床环境中有很大的应用潜力。